Supo-Aromasin

BELIGAS PHARMACEUTICALS SUPO-AROMASIN

Supo-Aromasin, a creation of pharmaceutical excellence by Beligas Pharmaceuticals, stands as a beacon of hormonal equilibrium. This medication is distinguished by its primary active ingredient, Exemestane 25 mg.

DRUG COMPOSITION

Each Supo-Aromasin tablet encapsulates 25 mg of Exemestane, a potent aromatase inhibitor crucial in hormonal modulation.

PHARMACEUTICAL FORM

Supo-Aromasin is formulated as oral tablets, ensuring precision in dosage administration and ease of use.

PHARMACEUTICAL GROUP AND ATC CODE

Pharmaceutical Group: Antineoplastic and Immunomodulating Agents
ATC Code: L02BG06 (Exemestane)

PHARMACOLOGICAL PROPERTIES

Exemestane, an aromatase inhibitor, plays a pivotal role in suppressing estrogen production, making it a valuable asset in hormonal management.

PROFILE

• Chemical name: (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione
• Chemical formula: C20H24O2
• Percentage of anabolic activity: Not a steroid
• Percentage of androgenic activity: Not a steroid
• Active half life: Approximately 24 hours
• Recommended dosage: 25 mg per day for breast cancer; may vary in other applications
• Acne: Not reported
• Bloating (water retention): Not reported
• HBR: Low
• Hepatic toxicity: Rare
• Aromatization: Inhibits aromatase, reducing estrogen conversion

THERAPEUTICAL INDICATIONS

Supo-Aromasin finds therapeutic application in:

• Treating hormone receptor-positive breast cancer in postmenopausal women.
• Countering estrogen-related side effects in certain hormone therapies.

DOSES AND METHOD OF ADMINISTRATION

Commence therapy with 25 mg once daily. Dosage adjustments may be made based on individual response and specific indications.

CYCLE/STACKING

Solo Cycle:

• Dosage: Initiate with 25 mg/day.
• Cycle Length: Tailor the duration in accordance with medical guidance.

Cutting Cycle:

• Supo-Aromasin is an essential component in cutting cycles for managing estrogen levels.
• Stacking: Combine with suitable steroids for optimal results.

Bulking Cycle:

• Limited application in bulking cycles; mainly employed for estrogen control.
• Stacking: Combine with appropriate compounds under professional supervision.

POST CYCLE THERAPY

Utilized in post-cycle therapy to mitigate estrogen rebound effects. Dosage: Tailored to individual needs, often starting at 25 mg/day.

SIDE EFFECTS

Potential side effects include fatigue, hot flashes, and joint pain. Vigilant monitoring is crucial to promptly address any adverse reactions.

CONTRAINDICATIONS

Supo-Aromasin is contraindicated in premenopausal women, individuals with hypersensitivity to Exemestane, and severe liver impairment.

OVERDOSE

In case of suspected overdose, seek immediate medical attention. Symptoms may include dizziness and nausea.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE:

Caution is advised in patients with hepatic disorders. Regular monitoring of bone health may be recommended.

INTERACTIONS WITH OTHER DRUGS

Exemestane may interact with certain medications. Consultation with a healthcare professional is imperative to avoid potential drug interactions.

PRESENTATION, PACKAGING

25 mg per tablet, 50 tablets in bottle.

STORAGE

Store Supo-Aromasin at controlled room temperature, shielded from light and moisture.

DELIVERY TO THE USA

Supo-Aromasin is available for secure and discreet delivery to the USA through authorized suppliers.

LEGAL STATUS

Supo-Aromasin is a prescription medication. Adherence to local regulations regarding purchase and use is essential.

Note: This information is for educational purposes only and does not substitute professional medical advice. Consult with a healthcare professional for personalized guidance on the use of Supo-Aromasin.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Beligas Pharmaceuticals
USA

EXTERNAL LINKS

• Exemestane Wiki, wikipedia.org
• Exemestane: Uses, Dosage, Side Effects, Warnings, drugs.com
• Exemestane Oral: Uses, Side Effects, Interactions, Pictures, webmd.com.